JP2022532766A5 - - Google Patents

Info

Publication number
JP2022532766A5
JP2022532766A5 JP2021568514A JP2021568514A JP2022532766A5 JP 2022532766 A5 JP2022532766 A5 JP 2022532766A5 JP 2021568514 A JP2021568514 A JP 2021568514A JP 2021568514 A JP2021568514 A JP 2021568514A JP 2022532766 A5 JP2022532766 A5 JP 2022532766A5
Authority
JP
Japan
Prior art keywords
agent according
eflornithine
sulindac
patient
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532766A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033080 external-priority patent/WO2020236562A1/en
Publication of JP2022532766A publication Critical patent/JP2022532766A/ja
Publication of JP2022532766A5 publication Critical patent/JP2022532766A5/ja
Pending legal-status Critical Current

Links

JP2021568514A 2019-05-17 2020-05-15 家族性腺腫性ポリポーシスを処置するための方法 Pending JP2022532766A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849590P 2019-05-17 2019-05-17
US62/849,590 2019-05-17
PCT/US2020/033080 WO2020236562A1 (en) 2019-05-17 2020-05-15 Methods for treating familial adenomatous polyposis

Publications (2)

Publication Number Publication Date
JP2022532766A JP2022532766A (ja) 2022-07-19
JP2022532766A5 true JP2022532766A5 (cg-RX-API-DMAC7.html) 2023-05-16

Family

ID=70978606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021568514A Pending JP2022532766A (ja) 2019-05-17 2020-05-15 家族性腺腫性ポリポーシスを処置するための方法

Country Status (6)

Country Link
US (3) US10945981B2 (cg-RX-API-DMAC7.html)
EP (1) EP3968971A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022532766A (cg-RX-API-DMAC7.html)
CN (1) CN114096240A (cg-RX-API-DMAC7.html)
TW (1) TWI917322B (cg-RX-API-DMAC7.html)
WO (1) WO2020236562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ792518A (en) * 2016-10-06 2023-04-28 Orbus Therapeutics Inc Formulations for administration of eflornithine
TWI917322B (zh) * 2019-05-17 2026-03-11 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
WO2026013052A1 (en) * 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of treating familial adenomatous polyposis
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えctla4ポリペプチドおよびその製造方法
US5456908A (en) 1994-03-01 1995-10-10 The University Of Kentucky Research Foundation Polyamine-polyamine and polyamine-protein transport inhibitor conjugates and their use as pharmaceuticals and in research relating to polyamine transport
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
EP0886519A1 (en) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
EP1067919A1 (en) 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo and sulindac combination in cancer chemoprevention
WO1999054283A1 (en) 1998-04-21 1999-10-28 Universite Laval Polyamine transport inhibitors
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
AU2001285232A1 (en) 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
EP1575584A4 (en) 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
DK2043637T3 (da) 2006-07-18 2012-05-07 Horizon Pharma Usa Inc Fremgangsmåder og medikamenter til administrering af ibuprofen
US20080248033A1 (en) * 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
CA2694389C (en) 2007-08-01 2016-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of pediatric tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5654986B2 (ja) 2008-06-30 2015-01-14 モーフオテク・インコーポレーテツド 抗gd2抗体並びにそれに関連する方法及び使用
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
MX2011005731A (es) 2008-12-08 2011-06-21 Procter & Gamble Composicion para el ciudado personal en la forma de un articulo que tiene un recubrimiento hidrofobo residente en la superficie.
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
SG176096A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
US9212131B2 (en) 2009-06-19 2015-12-15 University Of Central Florida Research Foundation, Inc. Polyamine transport inhibitors as novel therapeutics
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
EP2563936B1 (en) 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
EP2568978B1 (en) 2010-05-14 2019-04-24 Arizona Board of Regents on Behalf of University of Arizona Cancer prevention and treatment based on dietary polyamine content
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
EP2912193B1 (en) 2012-10-29 2018-08-29 Arizona Board of Regents on Behalf of University of Arizona Predictive markers for polyamine inhibitor cancer therapies
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
JP2018507910A (ja) * 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
JP2018536707A (ja) 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ,インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
TWI917322B (zh) * 2019-05-17 2026-03-11 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法

Similar Documents

Publication Publication Date Title
US6340695B1 (en) Rapid onset formulation
JP2931409B2 (ja) パラセタモール及びドンペリドンのフィルムコーティング錠
JP2021519288A5 (cg-RX-API-DMAC7.html)
CN110944638A (zh) 尼拉帕尼组合物
AU2001272243A1 (en) Rapid onset formulation
CN102395276A (zh) 硝唑尼特的控制释放药物剂型
CA2699209A1 (en) 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
AU2012349771A1 (en) Methods for treating cardiovascular disorder
JP7646646B2 (ja) セレキシパグを含む医薬組成物
JP2022553313A5 (cg-RX-API-DMAC7.html)
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
EP3013327A1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
ES2508490T3 (es) Formulación de trimetazidina con diferentes perfiles de liberación
JP2023528896A5 (cg-RX-API-DMAC7.html)
JP2025509278A5 (cg-RX-API-DMAC7.html)
CA2566331A1 (en) Oral delivery system
CN113557016A (zh) 衣壳组装调节剂固体配制品
CA2562009A1 (en) (r,r)-formoterol in combination with other pharmacological agents
JP2006528160A (ja) 抗血栓性化合物の口腔分散性医薬組成物
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤(乾式)
JP2007302688A (ja) 速効性処方剤
KR20260019468A (ko) 위식도 역류 질환(gerd) 치료를 위한 리나프라잔 글루레이트
JP2023507764A5 (cg-RX-API-DMAC7.html)
TR2022007368A2 (tr) Anti̇vi̇ral kompozi̇syonlar
WO2021053564A1 (en) Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof